Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorAbdul Razzak, Rana
dc.contributor.authorFlorence, Gordon John
dc.contributor.authorGunn-Moore, Francis James
dc.date.accessioned2019-06-25T14:30:06Z
dc.date.available2019-06-25T14:30:06Z
dc.date.issued2019-06-25
dc.identifier.citationAbdul Razzak , R , Florence , G J & Gunn-Moore , F J 2019 , ' Approaches to CNS drug delivery with a focus on transporter-mediated transcytosis ' , International Journal of Molecular Sciences , vol. 20 , no. 12 , 3108 . https://doi.org/10.3390/ijms20123108en
dc.identifier.issn1422-0067
dc.identifier.otherPURE: 259340916
dc.identifier.otherPURE UUID: 7dae642f-d836-47d3-81a2-db44acf43fa3
dc.identifier.otherORCID: /0000-0003-3422-3387/work/58984291
dc.identifier.otherORCID: /0000-0001-9921-4399/work/58984313
dc.identifier.otherWOS: 000473756000258
dc.identifier.otherScopus: 85068897518
dc.identifier.urihttp://hdl.handle.net/10023/17958
dc.descriptionFunding: Alzheimer’s Scotland, Alzheimer’s Society, Rosetrees Trust and RS MacDonald Charitable Trust.en
dc.description.abstractDrug delivery to the central nervous system (CNS) conferred by brain barriers is a major obstacle in the development of effective neurotherapeutics. In this review, a classification of current approaches of clinical or investigational importance for the delivery of therapeutics to the CNS is presented. This classification includes the use of formulations administered systemically that can elicit transcytosis-mediated transport by interacting with transporters expressed by transvascular endothelial cells. Neurotherapeutics can also be delivered to the CNS by means of surgical intervention using specialized catheters or implantable reservoirs. Strategies for delivering drugs to the CNS have evolved tremendously during the last two decades, yet, some factors can affect the quality of data generated in preclinical investigation, which can hamper the extension of the applications of these strategies into clinically useful tools. Here, we disclose some of these factors and propose some solutions that may prove valuable at bridging the gap between preclinical findings and clinical trials.
dc.format.extent43
dc.language.isoeng
dc.relation.ispartofInternational Journal of Molecular Sciencesen
dc.rights©2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/).en
dc.subjectCNS-targeted drug deliveryen
dc.subjectBlood-brain barrieren
dc.subjectReceptor-mediated transcytosisen
dc.subjectTransient BBB disruptionen
dc.subjectEfflux-pump inhibitionen
dc.subjectRing-opening metathesis polymerizationen
dc.subjectQD Chemistryen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectT-NDASen
dc.subject.lccQDen
dc.subject.lccRMen
dc.titleApproaches to CNS drug delivery with a focus on transporter-mediated transcytosisen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.EaSTCHEMen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews.School of Chemistryen
dc.contributor.institutionUniversity of St Andrews.Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews.Centre for Biophotonicsen
dc.contributor.institutionUniversity of St Andrews.Institute of Behavioural and Neural Sciencesen
dc.contributor.institutionUniversity of St Andrews.School of Biologyen
dc.identifier.doihttps://doi.org/10.3390/ijms20123108
dc.description.statusPeer revieweden
dc.identifier.urlhttps://www.mdpi.com/1422-0067/20/12/3108en


This item appears in the following Collection(s)

Show simple item record